A US drug pricing watchdog has raised the range by which it thinks Pfizer’s heart muscle disease drug tafamidis, marketed as ...

Samsung Biologics has so far secured at least five major contracts this year, and its latest with an unnamed Asia-based ...

APRIL antibody has passed a registrational test in a rare kidney disease, marking a significant win from its 2018 buyout of ...

In its quest to stay at the top of the obesity drug market, Eli Lilly is following in Novo Nordisk's footsteps by pursuing a ...

Activist investor Starboard Value said Pfizer's executives haven't delivered on what they once called one of the best ...

The future of how healthcare is delivered will be a hybrid mix of online and in-person care, much like how people shop both ...

AI may have a part to play in delivering mental health care, despite the empathetic and human nature of the specialty, but ...

FDA Commissioner Robert Califf criticized pharma companies on Monday for charging high prices for weight loss drugs. Califf ...

Editas Medicine is ousting its ex vivo sickle cell and beta thalassemia gene therapy to instead focus on an in vivo treatment ...

UCB will advance its anti-tau antibody for Alzheimer’s disease solo after Roche and Genentech walked away from the asset ...

The FDA handed a CRL to the Swedish biotech Camurus for its hormone disorder therapy over “facility-related deficiencies” at ...

AvenCell Therapeutics on Tuesday said it collected $112 million to continue clinical studies of two experimental acute ...